IRIS
TENTORI, LUCIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 51.430
EU - Europa 6.164
AS - Asia 4.819
SA - Sud America 582
AF - Africa 65
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 63.079
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 51.280
SG - Singapore 2.358
IT - Italia 1.965
CN - Cina 1.076
DE - Germania 763
UA - Ucraina 737
RU - Federazione Russa 546
FR - Francia 513
BR - Brasile 484
IE - Irlanda 427
HK - Hong Kong 395
VN - Vietnam 340
SE - Svezia 271
PL - Polonia 244
GB - Regno Unito 235
FI - Finlandia 217
JP - Giappone 152
KR - Corea 147
NL - Olanda 101
CA - Canada 87
BD - Bangladesh 77
IN - India 64
MX - Messico 40
CZ - Repubblica Ceca 34
ID - Indonesia 32
AR - Argentina 29
TR - Turchia 23
CO - Colombia 21
ES - Italia 21
AT - Austria 20
IQ - Iraq 18
BE - Belgio 17
ZA - Sudafrica 17
EG - Egitto 14
IL - Israele 13
LT - Lituania 13
PK - Pakistan 13
UZ - Uzbekistan 13
VE - Venezuela 13
PH - Filippine 12
EC - Ecuador 10
TN - Tunisia 10
AU - Australia 9
BG - Bulgaria 9
CH - Svizzera 9
CL - Cile 9
IR - Iran 9
MA - Marocco 9
MY - Malesia 9
EU - Europa 8
KE - Kenya 8
KG - Kirghizistan 7
AE - Emirati Arabi Uniti 6
KZ - Kazakistan 6
SA - Arabia Saudita 6
TW - Taiwan 6
JM - Giamaica 5
JO - Giordania 5
PE - Perù 5
PS - Palestinian Territory 5
PY - Paraguay 5
MK - Macedonia 4
NP - Nepal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
BH - Bahrain 3
DK - Danimarca 3
GT - Guatemala 3
NI - Nicaragua 3
OM - Oman 3
SY - Repubblica araba siriana 3
DO - Repubblica Dominicana 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
MW - Malawi 2
PT - Portogallo 2
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
GN - Guinea 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
KY - Cayman, isole 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
Totale 63.072
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.641
Wilmington 12.699
Houston 12.642
Ann Arbor 1.419
Singapore 1.259
Fairfield 1.117
Ashburn 843
Jacksonville 664
Chandler 621
San Jose 469
Seattle 445
Beijing 402
Dublin 401
Hong Kong 388
Cambridge 376
Rome 317
Medford 312
New York 284
Dearborn 228
Kraków 216
Santa Clara 199
Dallas 187
Milan 161
The Dalles 158
Lawrence 149
Los Angeles 132
Council Bluffs 118
Tokyo 114
Mülheim 113
Ho Chi Minh City 104
Buffalo 83
Moscow 77
Hanoi 68
Helsinki 67
Menlo Park 67
Zhengzhou 67
San Diego 59
Lauterbourg 56
Guangzhou 50
Boardman 45
São Paulo 44
Mountain View 42
Chicago 35
Frankfurt am Main 35
Redwood City 35
Munich 34
Shanghai 34
Falls Church 33
Civitavecchia 32
Nuremberg 32
Naples 31
San Mateo 28
Atlanta 27
Phoenix 27
Palo Alto 26
University Park 26
Columbus 25
Nanjing 25
Turin 25
London 24
San Francisco 23
Bari 22
Hefei 22
Prague 22
Verona 22
Catania 20
Florence 20
Jakarta 20
Palermo 20
Montreal 19
Norwalk 19
Toronto 19
Ottawa 18
Orem 17
Rio de Janeiro 17
Denver 16
Bologna 15
Brussels 15
Da Nang 15
Kansas City 15
Brescia 14
Brooklyn 14
Kunming 14
Mexico City 14
Saint Petersburg 14
Stockholm 14
Johannesburg 13
Nanchang 13
Redondo Beach 13
Brasília 12
Danville 12
Napoli 12
Porto Alegre 12
Tashkent 12
Belo Horizonte 11
Indiana 11
Pisa 11
Pune 11
Torino 11
Warsaw 11
Totale 54.062
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.566
L’attività fisica come terapia complementare: l’esempio delle malattie oncologiche 773
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 649
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 554
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 533
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 521
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 517
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 505
Targeted therapy for brain tumours: role of PARP inhibitors 498
Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) 494
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 489
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 482
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 481
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 481
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 479
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 477
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 476
Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds 472
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 471
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 469
Challenging resistance mechanisms to therapies for metastatic melanoma 468
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 466
Immunopharmacology of antitumor agents. 463
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 460
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 460
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 459
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 459
Una medicina che cambia: l’approccio all’ipercolesterolemia. 457
Exploiting Microglial Functions for the Treatment of Glioblastoma 457
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 455
Pharmacological strategies to increase the antitumor activity of methylating agents 454
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 454
New aspects of immune responses against mycobacteria: immunopharmacology studies 454
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 453
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 453
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 451
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 451
Modulation of GDF11 expression and synaptic plasticity by age and training 447
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 446
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 446
Thymic selection of the T-cell repertoire 443
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo 443
Chemotherapy in hairy cell leukemia. Preliminary results of a nonaggressive regimen 442
Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells 441
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 439
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 437
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 437
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 436
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 435
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engagement. Implications for the role of CD4 and CD8 accessory molecules in T cell differentiation 435
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 434
Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells 434
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 434
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 433
Role of DNA repair pathways in the control of common fragile sites expression. 432
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 431
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 431
IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3' dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro 430
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 430
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 429
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 429
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 428
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 427
Doping and Cancer 427
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 426
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 425
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 424
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 424
Acute rejection of interferon-treated leukemia cells injected into lethally irradiated syngeneic mice 423
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 422
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 422
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 422
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 421
Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester 420
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 419
Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells and increases temozolomide sensitivity of PARP-1 silenced melanoma cells. 415
Acquired hemoglobin H disease in a case of refractory anemia with excess of blasts (RAEB) evolving into acute nonlymphoid leukemia 414
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 413
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 413
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells 411
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. 410
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. 410
Inhibition of metastasis induced by triazene derivatives in mice bearing Lewis Lung Carcinoma (3LL): role of protein kinase C 409
Inhibition of poly(ADP-ribose) polymerase (PARP) increases the therapeutic efficacy of the G-quadruplex ligand RHPS4/irinotecan combination in colon cancer xenografts 406
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant 405
Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo 405
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 404
In vivo anti-angiogenic potential of a peptide that inhibits VEGFR-1 homodimerization and PlGF-induced migration of endothelial cells. 404
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinomas 404
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b. Secondo Progetto di ricerca Tubercolosi 404
null 404
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide combination against colon carcinoma 403
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3 403
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds 401
Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. 401
Chemopotentiation by PARP inhibitors in cancer therapy 400
PARP-1 inhibitor: a novel approach to enhance efficacy of chemotherapy. 399
PARP inhibitors for cancer treatment: an update on current clinical trials. 399
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b 399
Involvement of the mismatch repair system in temozolomide-induced apoptosis 398
Totale 45.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021110 0 0 0 0 0 0 0 0 0 0 0 110
2021/20221.494 64 214 110 66 32 110 95 68 106 107 76 446
2022/20231.923 202 107 61 268 115 430 163 97 180 41 176 83
2023/20241.176 100 36 81 65 109 342 86 60 47 47 65 138
2024/20253.572 139 858 398 208 136 312 150 192 350 181 323 325
2025/20265.523 407 252 776 334 490 179 601 731 665 659 238 191
Totale 63.310